Log in

NASDAQ:MACK - Merrimack Pharmaceuticals Stock Price, Forecast & News

$3.30
-0.10 (-2.94 %)
(As of 01/29/2020 01:28 AM ET)
Today's Range
$3.28
Now: $3.30
$3.50
50-Day Range
$3.11
MA: $3.44
$4.45
52-Week Range
$3.05
Now: $3.30
$7.50
Volume29,330 shs
Average Volume34,878 shs
Market Capitalization$44.10 million
P/E RatioN/A
Dividend YieldN/A
Beta2.17
Merrimack Pharmaceuticals, Inc operates as a clinical stage biopharmaceutical company that targets biomarker-defined cancers. The company is developing MM-310, an antibody-directed nanotherapeutic, which is in Phase I clinical trial to treat patients with solid tumors. Its preclinical product candidates include MM-401, an agonistic antibody targeting a novel immuno-oncology target; and MM-201, a stabilized agonist-Fc fusion protein targeting death receptors 4 and 5. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:MACK
CUSIP59032810
Phone617-441-1000

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$4.41 per share

Profitability

Net Income$-40,510,000.00

Miscellaneous

Employees27
Market Cap$44.10 million
Next Earnings Date3/4/2020 (Estimated)
OptionableOptionable

Receive MACK News and Ratings via Email

Sign-up to receive the latest news and ratings for MACK and its competitors with MarketBeat's FREE daily newsletter.


Merrimack Pharmaceuticals (NASDAQ:MACK) Frequently Asked Questions

What is Merrimack Pharmaceuticals' stock symbol?

Merrimack Pharmaceuticals trades on the NASDAQ under the ticker symbol "MACK."

How often does Merrimack Pharmaceuticals pay dividends? What is the dividend yield for Merrimack Pharmaceuticals?

Merrimack Pharmaceuticals announced a -- dividend on Wednesday, December 4th. Shareholders of record on Monday, December 16th will be given a dividend of $0.50 per share on Monday, December 23rd. The ex-dividend date is Friday, December 13th. View Merrimack Pharmaceuticals' Dividend History.

When did Merrimack Pharmaceuticals' stock split? How did Merrimack Pharmaceuticals' stock split work?

Shares of Merrimack Pharmaceuticals reverse split on the morning of Wednesday, September 6th 2017. The 1-10 reverse split was announced on Thursday, August 31st 2017. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, September 5th 2017. An investor that had 100 shares of Merrimack Pharmaceuticals stock prior to the reverse split would have 10 shares after the split.

How were Merrimack Pharmaceuticals' earnings last quarter?

Merrimack Pharmaceuticals Inc (NASDAQ:MACK) released its quarterly earnings results on Tuesday, November, 12th. The biopharmaceutical company reported ($0.05) earnings per share for the quarter. View Merrimack Pharmaceuticals' Earnings History.

When is Merrimack Pharmaceuticals' next earnings date?

Merrimack Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Wednesday, March 4th 2020. View Earnings Estimates for Merrimack Pharmaceuticals.

Has Merrimack Pharmaceuticals been receiving favorable news coverage?

News headlines about MACK stock have trended extremely negative recently, according to InfoTrie Sentiment. InfoTrie scores the sentiment of media coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Merrimack Pharmaceuticals earned a media sentiment score of -4.3 on InfoTrie's scale. They also assigned media stories about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the stock's share price in the immediate future. View News Stories for Merrimack Pharmaceuticals.

Are investors shorting Merrimack Pharmaceuticals?

Merrimack Pharmaceuticals saw a decline in short interest in December. As of December 31st, there was short interest totalling 533,500 shares, a decline of 6.8% from the December 15th total of 572,700 shares. Based on an average daily volume of 40,500 shares, the days-to-cover ratio is currently 13.2 days. Approximately 4.2% of the company's stock are sold short. View Merrimack Pharmaceuticals' Current Options Chain.

Who are some of Merrimack Pharmaceuticals' key competitors?

What other stocks do shareholders of Merrimack Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Merrimack Pharmaceuticals investors own include Agenus (AGEN), Rite Aid (RAD), Inovio Pharmaceuticals (INO), Anavex Life Sciences (AVXL), Novavax (NVAX), Amicus Therapeutics (FOLD), Gilead Sciences (GILD), Bausch Health Companies (BHC), Exelixis (EXEL) and Verastem (VSTM).

Who are Merrimack Pharmaceuticals' key executives?

Merrimack Pharmaceuticals' management team includes the folowing people:
  • Dr. Richard Peters, Pres, CEO & Director (Age 56)
  • Ms. Jean M. Franchi, CFO & Treasurer (Age 53)
  • Mr. Jeffrey A. Munsie, Gen. Counsel, Head of Corp. Operations & Sec. (Age 42)
  • Dr. Daryl C. Drummond Ph.D., Head of Research (Age 50)
  • Dr. Sergio L. Santillana, Chief Medical Officer (Age 56)

How do I buy shares of Merrimack Pharmaceuticals?

Shares of MACK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Merrimack Pharmaceuticals' stock price today?

One share of MACK stock can currently be purchased for approximately $3.30.

How big of a company is Merrimack Pharmaceuticals?

Merrimack Pharmaceuticals has a market capitalization of $44.10 million. Merrimack Pharmaceuticals employs 27 workers across the globe.View Additional Information About Merrimack Pharmaceuticals.

What is Merrimack Pharmaceuticals' official website?

The official website for Merrimack Pharmaceuticals is http://www.merrimackpharma.com/.

How can I contact Merrimack Pharmaceuticals?

Merrimack Pharmaceuticals' mailing address is ONE KENDALL SQUARE SUITE B7201, CAMBRIDGE MA, 02139. The biopharmaceutical company can be reached via phone at 617-441-1000 or via email at [email protected]


MarketBeat Community Rating for Merrimack Pharmaceuticals (NASDAQ MACK)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  389 (Vote Outperform)
Underperform Votes:  291 (Vote Underperform)
Total Votes:  680
MarketBeat's community ratings are surveys of what our community members think about Merrimack Pharmaceuticals and other stocks. Vote "Outperform" if you believe MACK will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MACK will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 1/29/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel